SMAD4 and prostate cancer: SMAD4, a critical component of the TGF-β signaling cascade, is inactivated in a subset of advanced prostate cancers through promoter hypermethylation [14] or somatic mutation [10], and its expression is reduced in metastatic prostate cancer [11].